These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8695265)

  • 21. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
    De Rossi G; Marroni P; Paganuzzi M; Mauro FR; Tenca C; Zarcone D; Velardi A; Molica S; Grossi CE
    Leukemia; 1997 Jan; 11(1):134-41. PubMed ID: 9001429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
    Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
    Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
    Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
    Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiprostasome antibody titres in benign and malignant prostate disease.
    Minelli A; Ronquist G; Carlsson L; Mearini E; Nilsson O; Larsson A
    Anticancer Res; 2005; 25(6C):4399-402. PubMed ID: 16334115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble CD44 splice variants in metastasizing human breast cancer.
    Martin S; Jansen F; Bokelmann J; Kolb H
    Int J Cancer; 1997 Aug; 74(4):443-5. PubMed ID: 9291436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
    Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
    Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.
    Kanoh Y; Ohtani N; Ohara T; Mashiko T; Ohtani S; Egawa S; Baba S; Ohtani H
    Oncol Rep; 2001; 8(3):515-9. PubMed ID: 11295072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
    Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC
    J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
    Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
    Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma.
    Gansauge F; Gansauge S; Rau B; Scheiblich A; Poch B; Schoenberg MH; Beger HG
    Cancer; 1997 Nov; 80(9):1733-9. PubMed ID: 9351541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH.
    Kastelan M; Kovacić K; Tarle R; Kraljić I; Tarle M
    Anticancer Res; 1997; 17(3B):1671-5. PubMed ID: 9179216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis.
    Kittl EM; Haberhauer G; Ruckser R; Selleny S; Rech-Weichselbraun I; Hinterberger W; Bauer K
    Rheumatol Int; 1997; 16(5):181-6. PubMed ID: 9032816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
    Lokant MT; Naz RK
    Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
    Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
    Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.
    Kalantari E; Asgari M; Nikpanah S; Salarieh N; Asadi Lari MH; Madjd Z
    Pathol Oncol Res; 2017 Oct; 23(4):793-802. PubMed ID: 28083789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anatomoclinical and biologic correlations in prostatic pathology. Apropos of 150 case reports].
    Amiel J; Chevallier D; Peyrottes A; Benoliel J; Toubol J
    Ann Urol (Paris); 1989; 23(6):528-30. PubMed ID: 2482700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
    Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.